Reuters Health Information: Liver transplant "excellent" option for kids with liver tumors
Liver transplant "excellent" option for kids with liver tumors
Last Updated: 2015-09-02
By Will Boggs MD
NEW YORK (Reuters Health) - Liver transplant combined with
chemotherapy provides long-term disease-free survival in
children with hepatoblastoma and hepatocellular cancer (HCC),
according to a new study.
"Patients with metastatic hepatoblastoma (HBL) can have
excellent results with transplantation," Dr. C. Andrew Bonham
from Stanford University School of Medicine in Palo Alto,
California, told Reuters Health by email. "Children with HCC
have different outcomes (better) than adults."
Liver tumors in children are rare. The annual incidence of
primary liver malignancies in children and adolescents is around
one in 2 million, with HBL representing about two-thirds and HCC
accounting for less than 25% of cases.
In order to clarify the long-term outcomes of liver
transplant for unresectable HBL and HCC, Dr. Bonham's team
reviewed their experience with 40 patients (30 with HBL and 10
with HCC) who underwent transplant from 1997 through 2014.
Disease-free survival 10 years after transplant was 82% in
the HBL group and 78% in the HCC group. Overall 10-year survival
was 84% in the HBL group and 72% in the HCC group, and graft
survival was 83% in the HBL group and 85% in the HCC group.
Risk factors for HBL recurrence included having PRETEXT
stage IV disease or tumor rupture and being older at the time of
the transplant, the researchers report in JAMA Surgery, online
August 26.
Children who developed HBL recurrence also spent about twice
as long on the transplant waiting list as children without
recurrence (mean 31 days vs 15 days, p<0.01).
In the HCC group, tumor size, vascular invasion, and time to
transplant were not associated with recurrence, but being older
at the time of transplant and having metastatic disease were
significant risk factors for recurrence.
"HBL patients should be considered for transplant early,"
Dr. Bonham concluded. "Eradication of metastatic disease with
chemotherapy and surgery should be followed by timely
transplant. Prolonged waiting is associated with poorer
prognosis and interrupts optimal chemotherapy. Children with HCC
that develops in the absence of chronic viral hepatitis have a
better prognosis, and should be transplanted regardless of Milan
criteria if the tumor is confined to the liver and without
vascular invasion."
Dr. Ronald W. Busuttil from David Geffen School of Medicine
at UCLA, Los Angeles, California, who coauthored an invited
commentary on the report, told Reuters Health, "Liver
transplantation, either primary or salvage, has outstanding
outcomes in this lethal cancer. Registry studies such as the
pediatric liver unresectable tumor observatory (PLUTO) and
single center experiences such as our own at UCLA have
demonstrated an expected long-term liver survival of 80 to 90%.
This is superior to what can be achieved with any other modality
of therapy including chemotherapy, ablative therapy, or surgery
alone."
"These data indicated that proper and timely referral is
essential and liver transplantation for a child without
significant extrahepatic disease should be considered as
first-line therapy," Dr. Busuttil said.
A second report, also online August 26 in JAMA Surgery,
describes damage control as a strategy to manage postreperfusion
hemodynamic instability and coagulopathy after liver transplant.
The approach "includes completion of portal venous and
hepatic arterial anastomoses for allograft reperfusion, deferral
of biliary reconstruction, intra-abdominal packing, and
resuscitation in the intensive care unit before packing removal,
biliary reconstruction, and closure of the abdomen within 48
hours," Dr. Vatche G. Agopian from David Geffen School of
Medicine at UCLA and colleagues write.
According to their review of 1,813 adult patients who
underwent liver transplantation, 8.3% required damage control.
These patients had longer hospital stay, higher infection rates,
higher rates of graft nonfunction, and higher mortality within
30 days, compared with patients not requiring damage control.
"Despite recipients requiring damage control being
significantly sicker to begin with compared to recipients who
underwent 1-stage transplant, if only one additional operation
was required, the outcomes were similar," Dr. Agopian told
Reuters Health by email.
"As in trauma surgery, staying in the operating room can
sometimes serve to worsen the cycle of bleeding, coagulopathy,
acidosis, and hypothermia, and our study at least shows that
this damage control strategy itself is not deleterious, and
potentially mitigates the negative outcomes that may arise from
staying in the operating room too long," he said.
SOURCE: http://bit.ly/1hU2AoK, http://bit.ly/1UmT4eQ and
http://bit.ly/1L558XU
JAMA Surg 2015.
|